PURPOSE: The therapeutic activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab in gastric cancer is currently being investigated. Reliable biomarkers for the identification of patients who are likely to benefit from the treatment are not available. The aim of the study was to examine the drug sensitivity of five gastric cancer cell lines towards cetuximab as a single agent and to establish predictive markers for chemosensitivity in this cell culture model. The effect of a combination of cetuximab with chemotherapy was compared between a sensitive and a nonsensitive cell line. METHODS: EGFR expression, activation and localisation, the presence and subcellular localisation of the cell adhesion molecule E-cadherin as well as MET activation were examined by Western blot analysis, flow cytometry and immunofluorescence staining. Cells were treated with varying concentrations of cetuximab and cisplatin and 5-fluorouracil in tumour-relevant concentrations. The biological endpoint was cell viability, which was measured by XTT cell proliferation assay. Response to treatment was evaluated using statistical methods. RESULTS: We assessed the activity of cetuximab in five gastric cancer cell lines (AGS, KATOIII, MKN1, MKN28 and MKN45). The viability of two cell lines, MKN1 and MKN28, was significantly reduced by cetuximab treatment. High EGFR expression and low levels of receptor activation were associated with cetuximab responsiveness. MET activation as well as mutations of KRAS and CDH1 (gene encoding E-cadherin) was associated with cetuximab resistance. CONCLUSION: These data indicate that our examinations may be clinically relevant, and the candidate markers should therefore be tested in clinical studies.
PURPOSE: The therapeutic activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab in gastric cancer is currently being investigated. Reliable biomarkers for the identification of patients who are likely to benefit from the treatment are not available. The aim of the study was to examine the drug sensitivity of five gastric cancer cell lines towards cetuximab as a single agent and to establish predictive markers for chemosensitivity in this cell culture model. The effect of a combination of cetuximab with chemotherapy was compared between a sensitive and a nonsensitive cell line. METHODS:EGFR expression, activation and localisation, the presence and subcellular localisation of the cell adhesion molecule E-cadherin as well as MET activation were examined by Western blot analysis, flow cytometry and immunofluorescence staining. Cells were treated with varying concentrations of cetuximab and cisplatin and 5-fluorouracil in tumour-relevant concentrations. The biological endpoint was cell viability, which was measured by XTT cell proliferation assay. Response to treatment was evaluated using statistical methods. RESULTS: We assessed the activity of cetuximab in five gastric cancer cell lines (AGS, KATOIII, MKN1, MKN28 and MKN45). The viability of two cell lines, MKN1 and MKN28, was significantly reduced by cetuximab treatment. High EGFR expression and low levels of receptor activation were associated with cetuximab responsiveness. MET activation as well as mutations of KRAS and CDH1 (gene encoding E-cadherin) was associated with cetuximab resistance. CONCLUSION: These data indicate that our examinations may be clinically relevant, and the candidate markers should therefore be tested in clinical studies.
Authors: Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: M Moehler; A Mueller; T Trarbach; F Lordick; T Seufferlein; S Kubicka; M Geißler; S Schwarz; P R Galle; S Kanzler Journal: Ann Oncol Date: 2010-11-30 Impact factor: 32.976
Authors: Gromoslaw A Smolen; Beth Muir; Gayatry Mohapatra; Anne Barmettler; Woo J Kim; Miguel N Rivera; Sara M Haserlat; Ross A Okimoto; Eunice Kwak; Sonika Dahiya; Judy E Garber; Daphne W Bell; Dennis C Sgroi; Lynda Chin; Chu-Xia Deng; Daniel A Haber Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701
Authors: Sergio Benavente; Shyhmin Huang; Eric A Armstrong; Alexander Chi; Kun-Tai Hsu; Deric L Wheeler; Paul M Harari Journal: Clin Cancer Res Date: 2009-02-03 Impact factor: 12.531
Authors: Gerald Li; Dean Pavlick; Jon H Chung; Todd Bauer; Bradford A Tan; Julio Peguero; Patrick Ward; Andre Kallab; Jose Bufill; Anthony Hoffman; Ahad Sadiq; Jeff Edenfield; Jie He; Matthew Cooke; Jason Hughes; Brady Forcier; Michelle Nahas; Phil Stephens; Siraj M Ali; Alexa B Schrock; Jeffrey S Ross; Vincent A Miller; Jeffrey P Gregg Journal: J Gastrointest Oncol Date: 2019-10
Authors: Marco Felkl; Kazmar Tomas; Matej Smid; Julian Mattes; Reinhard Windoffer; Rudolf E Leube Journal: PLoS One Date: 2012-09-27 Impact factor: 3.240
Authors: Tom Waddell; Ian Chau; David Cunningham; David Gonzalez; Alicia Frances Clare Okines; Alicia Frances; Clare Okines; Andrew Wotherspoon; Claire Saffery; Gary Middleton; Jonathan Wadsley; David Ferry; Wasat Mansoor; Tom Crosby; Fareeda Coxon; David Smith; Justin Waters; Timothy Iveson; Stephen Falk; Sarah Slater; Clare Peckitt; Yolanda Barbachano Journal: Lancet Oncol Date: 2013-04-15 Impact factor: 41.316
Authors: N C T van Grieken; T Aoyama; T Aoyma; P A Chambers; D Bottomley; L C Ward; I Inam; T E Buffart; K Das; T Lim; B Pang; S L Zhang; I B Tan; B Carvalho; D A M Heideman; Y Miyagi; Y Kameda; T Arai; G A Meijer; A Tsuburaya; P Tan; T Yoshikawa; H I Grabsch Journal: Br J Cancer Date: 2013-03-19 Impact factor: 7.640